The first-quarter earnings season has come to an end for large drug and biotech companies, with Bayer reporting its results ...

Several drug stocks are at risk as the Federal Trade Commission is going after pharmaceutical companies that it alleges are ...

When Amylyx Pharmaceuticals found out its ALS drug Relyvrio didn't work, the company took the unusual step of voluntarily ...

After pressure from activist investors, BioMarin Pharmaceutical Inc. is slashing jobs and reshuffling its drug portfolio.

With pharmaceutical mergers more common, the FTC is taking a hard look at pharmacy benefit managers and antitrust concerns.

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American ...

Eisai and partner Biogen said on Tuesday that the Japanese drugmaker has begun submitting data on a rolling basis to the US ...

NewVale Capital now has nearly $200 million total under management and plans to invest between $10 million and $50 million in ...

This analysis did not drill down to the level of individual patents to assess their legitimacy, Kesselheim stressed. However, ...

Cancer drug trials are structured to promote high doses, which then become routine patient care. In the face of evidence that ...

Major drug companies have been snatching up biotech companies that developing antibody-drug conjugates (ADCs) targeting a ...